3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Skin Neoplasms
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hot Flashes
2
Vulvodynia
1
Thromboembolism
1
Severe Acute Respiratory Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Hemorrhage
1
Pleural Effusion, Malignant
1
Platinum Resistant Ovarian Cancer
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Neutropenia
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Interventions
rozanolixizumab
5
zilucoplan
4
eculizumab
4
efgartigimod alfa
3
Rituximab
2
Prednisone
2
Amifampridine
2
thymoglobulin
1
satralizumab
1
rhoA GTP-Binding Protein
1
ravulizumab
1
iscalimab
1
inebilizumab
1
gamma-Globulins
1
Thymectomy
1
Sugars
1
Steroids
1
Sodium Chloride
1
Robotic Surgical Procedures
1
Prednisolone
1
Methylprednisolone
1
Methotrexate
1
Mesna
1
Hizentra
1
Hematopoietic Stem Cell Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Fluid Therapy
1
Cyclophosphamide
1
Acupuncture Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Myasthenia Gravis
×
Sodium Chloride
×
Clear all
NCT02950155
2024-10-26
Rinomax
Karolinska Institutet
Phase 3
Completed
47 enrolled
24 charts